Refine Results
  1. "S. Karger AG"
Formats
  1. Meeting Abstract (240)
  2. Journal Article (225)
  3. Book Section (20)
  4. Review (13)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (195)
  2. Solid Tumor Oncology Division (111)
  3. Center for Hematologic Malignancies (74)
  4. Hematologic Malignancies, Division of (68)
  5. Sloan Kettering Institute Faculty (53)
  6. Sloan Kettering Institute Postdocs (51)

More Groups

People
  1. Lisa Bodei (31)
  2. Robert Motzer (23)
  3. Alexander Drilon (16)
  4. Oscar Lin (16)
  5. Raju Chaganti (16)
  6. Steven Hajdu (15)

More People

Years
  1. 2022 (1)
  2. 2021 (31)
  3. 2020 (51)
  4. 2019 (40)
  5. 2018 (30)
  6. 2017 (25)

More Years

Publications
  1. Oncology Research and Treatment (134)
  2. Acta Cytologica (55)
  3. Neuroendocrinology (49)
  4. Cytogenetics and Cell Genetics (48)
  5. Acta Haematologica (30)
  6. Onkologie (19)

More Publications

Publishers
  1. S. Karger AG (510)

Results (510)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Advances in the etiology, detection, and clinical management of seborrheic keratoses
    Review

    Sun, M. D.; Halpern, A. C.
    Dermatology (2022)

    Fulltext@MSK | Save
  • Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms
    Meeting Abstract

    Grünwald, V.; Hutson, T.; Choueiri, T. K.; Motzer, R.; Rha, S. Y.; Alyasova, A.; Merchan, J.; Gurney, H.; Peer, A.; Takagi, T.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • MERMAID-2: Phase 3 study of durvalumab in patients with resected, stage II-III NSCLC who become MRD plus after curative-intent therapy
    Meeting Abstract

    Reinmuth, N.; Spigel, D.; Peters, S.; Ahn, M. J.; Tsuboi, M.; Chaft, J.; Harpole, D.; Barlesi, F.; Abbosh, C.; Mann, H.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) with adjuvant nivolumab (NIVO) vs placebo (PBO) after radical resection for high-risk muscle-invasive urothelial carcinoma (MIUC): Results from the phase 3 CheckMate 274 trialep138
    Meeting Abstract

    Gschwend, J. E.; Bajorin, D.; Galsky, M.; Broughton, E.; Braverman, J.; Koon, H.; Maira-Arce, M.; Hamilton, M.; Shi, L.; Guo, S.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • The CAR-HEMATOTOX model identifies patients with a high risk for CAR T-cell related hematotoxicity and is associated with prolonged hospitalization and poor prognosis
    Meeting Abstract

    Rejeski, K.; Perez, A.; Sesques, P.; Berger, C.; Jentzsch, L.; Mougiakakos, D.; Frölich, L.; Ackermann, J.; Bücklein, V.; Blumenberg, V.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Outcomes in patients (pts) aged ≥ 65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Meeting Abstract

    Hegewisch-Becker, S.; Oliveira, M.; Traina, T.; Tolaney, S. M.; Loirat, D.; Punie, K.; Hurvitz, S. A.; Lynce, F.; Hamilton, E.; Nanda, R.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Matterhorn: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - A randomized, doubleblind, placebo-controlled, phase 3 study
    Meeting Abstract

    Al-Batran, S. E.; Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Hyung, W. J.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S. H.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Spotlight: Phase 3 study of Zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line claudin18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Meeting Abstract

    Lordick, F.; Shitara, K.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P.; Ilson, D.; Kim, S.; Shah, M. A.; Van Cutsem, E.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Polo: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
    Meeting Abstract

    Arnold, D.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS
    Meeting Abstract

    Reichardt, P.; Heinrich, M.; George, S.; Zalcberg, J. R.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save